在儿科ECMO中优化CKRT的抗凝剂:区域酸盐抗凝剂的有效性
Ayşen Durak Aslan1, Özge Aydın2, Hacer Uçmak3
1Department of Pediatric Critical Care, Ankara University School of Medicine, Ankara, Turkey. draysendurak@gmail.com.
Pediatric nephrology (Berlin, Germany)
|September 8, 2025
概括
区域酸盐抗凝剂与肝素相结合可能会延长儿科ECMO患者的连续脏替代疗法循环寿命. 与单独使用肝素相比,这种方法减少了由于凝血引起的电路变化.
科学领域:
- 儿科重症监护医学 儿科重症监护医学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 支持心肺血管的支持.
背景情况:
- 身体外膜氧化 (ECMO) 是重症儿科患者的生命支持措施.
- 在ECMO期间,经常需要持续置换疗法 (CKRT),以治疗流体过载和急性损伤.
- 在ECMO期间用于CKRT的抗凝血策略对于电路通透性和患者的结果至关重要.
研究的目的:
- 评价区域酸盐抗凝剂 (RCA) 加非分离肝素 (UFH) 与UFH单独用于儿科ECMO患者的CKRT的疗效.
- 为了比较两种抗凝血策略之间的CKRT电路寿命和由于凝血引起的电路变化.
主要方法:
- 从2014年6月到2023年5月,对儿童患者进行ECMO需要CKRT的回顾性描述性研究.
- 患者被分为两个组:UFH + RCA和UFH单独.
- 估计了CKRT电路寿命,并分析了由于凝血而导致的电路变化.
主要成果:
- 在110名儿科ECMO患者中,64人需要CKRT.
- 与UFH组 (52小时) 相比,UFH + RCA组显示了较长CKRT电路寿命 (84小时) 的趋势.
- 由于凝血而导致的电路变化在UFH + RCA组 (31.7%) 与UFH组 (58.1%,p=0.00) 相比显著较低,时间偏好UFH + RCA (p=0.02) 的统计学上显著差异.
结论:
- 在儿科ECMO患者中,用于CKRT的辅助区域酸盐抗凝药可以通过减少与凝血相关的电路变化来延长电路寿命.
- 这项研究是第一个将UFH + RCA与UFH单独用于该人群中的CKRT进行比较的研究.
- 需要进一步的前性研究来证实这些发现.
相关概念视频
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
180
Continuous Renal Replacement Therapy (CRRT) is an essential intervention for patients experiencing severe kidney dysfunction. This therapy offers a continuous mechanism for removing fluids and toxins from the bloodstream, leveraging the patient’s blood pressure to facilitate filtration through a specialized filter. This method contrasts with intermittent dialysis, providing a gentler and more consistent removal of waste products and excess fluid, which is particularly beneficial in...
180
Venous Thrombosis III: Interprofessional Care
280
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
280
Continuous Renal Replacement Therapy
869
Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
869
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
329
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
329
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.7K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.7K
Cardiopulmonary Resuscitation IV: Pharmacological Management
679
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
679


